MRKR

Fiyat (1 Yıl)

Katılım Finansı Tarama Oranları

Oranlar AAOIFI tabanlı tarama dosyasından alınmıştır; fetva niteliği taşımaz.

Şirket Hakkında

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.